Compare BRBS & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBS | ELDN |
|---|---|---|
| Founded | 1893 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.2M | 291.8M |
| IPO Year | 2015 | 2014 |
| Metric | BRBS | ELDN |
|---|---|---|
| Price | $4.01 | $2.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 1.3M | 947.9K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 24.78% | N/A |
| EPS Growth | ★ 135.48 | 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $111,284,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.99 | N/A |
| 52 Week Low | $3.23 | $1.35 |
| 52 Week High | $4.79 | $4.60 |
| Indicator | BRBS | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 68.72 | 30.37 |
| Support Level | $3.88 | $2.68 |
| Resistance Level | $4.08 | $3.21 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 95.65 | 5.44 |
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance, and others. It generates the majority of its revenue from commercial banking.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.